1.
Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis
by Wirka, Robert C
Nature medicine, 2019, Vol.25 (8), p.1280-1289
2.
Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints t...
by Kobayashi, Tohru, Dr
The Lancet (British edition), 2012, Vol.379 (9826), p.1613-1620
3.
Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study
by Blaha, Michael J, Dr
The Lancet (British edition), 2011, Vol.378 (9792), p.684-692
4.
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
by Fayad, Zahi A, Prof
The Lancet (British edition), 2011, Vol.378 (9802), p.1547-1559
5.
Cardiovascular effects of marine omega-3 fatty acids
by Saravanan, Palaniappan, Dr
The Lancet (British edition), 2010, Vol.376 (9740), p.540-550
6.
Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis
by Chen, Shaojie
Heart, 2013, Vol.99 (2), p.76-82
7.
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development
by Wilensky, Robert L
Nature medicine, 2008, Vol.14 (10), p.1059-1066
8.
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
by Shepherd, James
The Lancet (British edition), 2002, Vol.360 (9346), p.1623-1630
9.
The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned?
by Miller, Virginia M
Menopause (New York, N.Y.), 2019, Vol.26 (9), p.1071-1084
10.
From Vulnerable Plaque to Vulnerable Patient—Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force Report
by Naghavi, Morteza
The American journal of cardiology, 2006, Vol.98 (2), p.2-15
11.
Lupus Atherosclerosis Prevention Study (LAPS)
by Petri, M A
Annals of the rheumatic diseases, 2011, Vol.70 (5), p.760-765
12.
Factors of Health in the Protection against Death and Cardiovascular Disease among Adults with Subclinical Atherosclerosis
by Rifai, Mahmoud Al Mahmoud Al
The American heart journal, 2017, Vol.198, p.180-188
13.
Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACC...
by Nicholls, Stephen J., MBBS, PhD
The American heart journal, 2015, Vol.170 (6), p.1061-1069
14.
Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
by Jaeger, Beate R
Nature clinical practice cardiovascular medicine, 2009, Vol.6 (3), p.229-239
15.
Antiplatelet therapy for secondary prevention of coronary artery disease
by Pilgrim, Thomas
Heart, 2014, Vol.100 (22), p.1750-1756
16.
Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future
by Clarkson, Thomas B.
Menopause (New York, N.Y.), 2013, Vol.20 (3), p.342-353
17.
Associations between antiretroviral use and subclinical coronary atherosclerosis
by Thomas, Guajira P
AIDS (London), 2016, Vol.30 (16), p.2477-2486
18.
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods
by Buse, John B., MD, PhD
The American journal of cardiology, 2007, Vol.99 (12), p.S21-S33
19.
A protective smooth muscle cell transition in atherosclerosis
by Pan, Huize
Nature medicine, 2019, Vol.25 (8), p.1194-1195
20.
Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial
by Singh, Ram B
The Lancet (British edition), 2002, Vol.360 (9344), p.1455-1461
